Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the Europe digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.6% from 2019 to 2026. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.
The Europe digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026, which assists to identify the prevailing market opportunities.
- An in-depth analysis of Europe regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate this region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the Europe digital therapeutics market is provided.
KEY MARKET SEGMENTS
- Cardiovascular Disease (CVD)
- Central Nervous System (CNS) Disease
- Respiratory Disease
- Smoking Cessation
- Gastrointestinal Disorder (GID)
By Product Type
By Product Type
- Business-to-Business (B2B)
- Healthcare Provider
- Business-to-Consumer (B2C)
- Rest of Europe
KEY MARKET PLAYERS
- Fitbit, Inc. (Twine Health, Inc.)
- Medtronic Plc.
- Novartis International AG (Pear Therapeutics, Inc.)
- Resmed, Inc. (Propeller Health)
- Voluntis, Inc.
- Ada Health GmbH
- Cognifit ltd
- Caterna Vision GmbH
- Sonormed GmbH
- Kaia Health
The other players in the value chain include (profiles not included in the report):
- Veeva Systems
- Syneos Health
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.2.3. Top Player Positioning, 2018
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
188.8.131.52. Increase in Adoption of Smartphones and Tablets Coupled With Healthcare Apps
184.108.40.206. Growth in Need to Control Healthcare Costs
220.127.116.11. Rise in Incidences of Chronic Diseases
18.104.22.168. Lack of Awareness Regarding Digital Therapeutics in Developing Countries
22.214.171.124. Patient Data Privacy Concerns
126.96.36.199. Emerging Markets Offer Significant Growth Opportunities
4.1.1. Market Size and Forecast
4.2.1. Key Market Trends and Growth Opportunities
4.2.2. Market Analysis, by Country
4.3.1. Key Market Trends and Growth Opportunities
4.3.2. Market Analysis, by Country
4.4. Cardiovascular Diseases
4.4.1. Key Market Trends and Growth Opportunities
4.4.2. Market Analysis, by Country
4.5. Central Nervous System (Cns) Diseases
4.5.1. Key Market Trends and Growth Opportunities
4.5.2. Market Analysis, by Country
4.6. Gastrointestinal Disorder
4.6.1. Key Market Trends and Growth Opportunities
4.6.2. Market Analysis, by Country
4.7. Respiratory Diseases
4.7.1. Key Market Trends and Growth Opportunities
4.7.2. Market Analysis, by Country
4.8. Smoking Cessation
4.8.1. Key Market Trends and Growth Opportunities
4.8.2. Market Analysis, by Country
4.9.1. Key Market Trends and Growth Opportunities
4.9.2. Market Analysis, by Country
5.1.1. Market Size and Forecast
5.2.1. Market Analysis, by Country
5.3.1. Market Analysis, by Country
6.1.1. Market Size and Forecast
6.2. Business-To-Business (B2B)
6.2.1. Market Size and Forecast, by Type
188.8.131.52.1. Market Size and Forecast
184.108.40.206. Healthcare Providers
220.127.116.11.1. Market Size and Forecast
18.104.22.168.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Business-To-Consumers (B2C)
6.3.1. Market Size and Forecast, by Type
22.214.171.124.1. Market Size and Forecast
126.96.36.199.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
7.2. Key Market Trends, Growth Factors, and Opportunities
7.3. Europe Digital Therapeutics Market, by Country
7.3.1. UK Digital Therapeutics Market, by Application
7.3.2. UK Digital Therapeutics Market, by Product Type
7.3.3. UK Digital Therapeutics Market, by Sales Channel
7.3.4. Germany Digital Therapeutics Market, by Application
7.3.5. Germany Digital Therapeutics Market, by Product Type
7.3.6. Germany Digital Therapeutics Market, by Sales Channel
7.3.7. France Digital Therapeutics Market, by Application
7.3.8. France Digital Therapeutics Market, by Product Type
7.3.9. France Digital Therapeutics Market, by Sales Channel
7.3.10. Italy Digital Therapeutics Market, by Application
7.3.11. Italy Digital Therapeutics Market, by Product Type
7.3.12. Italy Digital Therapeutics Market, by Sales Channel
7.3.13. Spain Digital Therapeutics Market, by Application
7.3.14. Spain Digital Therapeutics Market, by Product Type
7.3.15. Spain Digital Therapeutics Market, by Sales Channel
7.3.16. Russia Digital Therapeutics Market, by Application
7.3.17. Russia Digital Therapeutics Market, by Product Type
7.3.18. Russia Digital Therapeutics Market, by Sales Channel
7.3.19. Rest of Europe Digital Therapeutics Market, by Application
7.3.20. Rest of Europe Digital Therapeutics Market, by Product Type
7.3.21. Rest of Europe Digital Therapeutics Market, by Sales Channel
7.4. Europe Digital Therapeutics Market, by Application
7.5. Europe Digital Therapeutics Market, by Product Type
7.6. Europe Digital Therapeutics Market, by Sales Channel
8.1.1. Company Overview
8.1.2. Product Portfolio
8.1.3. Key Strategic Moves and Developments
8.2.1. Company Overview
8.2.2. Operating Business Segments
8.2.3. Product Portfolio
8.2.4. Key Strategic Moves and Developments
8.3. Caterna Vision GmbH
8.3.1. Company Overview
8.3.2. Operating Business Segments
8.3.3. Product Portfolio
8.4. Fitbit, Inc. (Twine Health, Inc.)
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Product Portfolio
8.4.4. Business Performance
8.5. Kaia Health
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.6. Medtronic plc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Novartis International AG (Pear Therapeutics, Inc.)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. Resmed, Inc. (Propeller Health)
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves and Developments
8.9. Sonormed GmbH
8.9.1. Company Overview
8.9.2. Product Portfolio
8.10. Voluntis, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments
Digital therapeutics is a subset of digital health, which delivers evidence-based therapeutic interventions to patients by software programs and devices to manage, prevent, and treat medical disorders. It utilizes digital and online health technologies to treat medical and psychological conditions. In addition, software applications help patients and physicians to track health data by tracking patient behavior. Moreover, digital therapeutics provides remote monitoring to improve long-term health problems.According to European Chronic Disease Alliance (ECDA), 85% of deaths in the European Union (EU) occur due to chronic diseases, including cardiovascular disease, cancer, diabetes, chronic respiratory disease, and mental illness. In addition, these chronic illnesses cost European economy around $124 billion a year. Whereas, digital therapeutics helps in lowering these healthcare costs. Moreover, digital therapeutics products can drive down a company’s health care costs by lowering usage of health insurance plans for acute problems.
Rise in utilization of smart devices and smartphones&tablets coupled with increase in incidenceof chronic diseases boosts the growth of the Europe digital therapeutics market. However, lack of awareness toward healthcare-associated applications and increase in concerns regarding patient data restrict the market growth. Conversely, high growth potential in the emerging markets offers lucrative opportunities for key market players operating in this segment.
Based on Application, Europe Digital Therapeutics Market is segmented into Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others. Depending upon product Type, the market is divided into software and device. By sales channel, the market is bifurcated into business-to-business (B2B) and business-to-consumer (B2C). Region wise, the market is studies across European countries including, UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.
Among applications, obesity segment is expected to grow at a high CAGR during the forecast period, owing to the increase in obese population. For instance, according to the WHO, in Europe, 58.7% of the population was overweight and 23.3% of population were obese in 2016, and this percentage is rising every year.
Amongproducts, in 2018, software segment helda dominant portion in the market,accounting for about 68.2% of Europe digital therapeutics market sharein 2018. This is mainly due to the increased penetration of smart phones and other devices mostly in developing economies. This further increases the use of digital therapeutics.
Key Findings Of The Study
Software is expected to be one of the most lucrative segments,registering a CAGR of 20.8% during the forecast period.
The business-to-consumers (B2C)segmentaccounted for maximum share in the Europe market in 2018, and is expected to grow at a CAGR of 21.1% during the forecast period.
UK dominated the Europedigital therapeutics market, and is projected to retain this trend throughout the forecast period.
Diabetes is accounted for the maximum share in 2018, in Europe, with registering a CAGR of 22.6% during the forecast period.
The key players operating in the Europe digital therapeutics market are Ada Health GmbH, CogniFit, Caterna Vision GmbH, Fitbit, Inc. (Twine Health, Inc.), Kaia Health, Medtronic Plc., Novartis International AG (Pear Therapeutics, Inc.), ResMed, Inc. (Propeller Health), Sonormed GmbH, and Voluntis, Inc.
The other players in the value chain include (profiles not included in the report)GlaxoSmithKline, Veeva Systems, and Syneos Health.
- Ada Health GmbH
- Caterna Vision GmbH
- Fitbit Inc. (Twine Health Inc.)
- Kaia Health
- Medtronic Plc.
- Novartis International AG (Pear Therapeutics Inc.)
- ResMed Inc. (Propeller Health)
- Sonormed GmbH
- Voluntis Inc
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.